ASCVD remains the leading cause of death worldwide despite the effectiveness of statin therapy in reducing low-density lipoprotein cholesterol (LDL-C) levels (Baigent et al., 2005; Roth et al., 2020). Additional therapeutic targets and adjunctive treatments are needed to address the burden arising from residual risk (Rosenson and Goonewardena, 2021). TGs play vital roles in physiology, ranging from energy storage and mobilization to inflammation, thrombosis, and hormone-like signaling (Zewinger et al., 2020; Norata et al., 2007). However, a causal relationship between TGs and ASCVDs remains controversial (Miller et al., 2011; Albrink and Man, 1959), recently culminating in the conflicting reports of two double-blinded randomized controlled trials (RCT), STRENGTH, and REDUCE-IT (Nicholls et al., 2020; Bhatt et al., 2019; Doi et al., 2021). Nevertheless, drug development for reducing TG-rich lipoproteins (TRL) is an active area of research and several targets have now been validated, including angiopoietin-like 3 (ANGPTL3) (Graham et al., 2017; Dewey et al., 2017; Musunuru et al., 2010; Gaudet et al., 2017), angiopoietin-like 4 (ANGPTL4) (Dewey et al., 2016), and apolipoprotein C-III (APOC3) (Gaudet et al., 2015; Crosby et al., 2014). Clinical trials are currently evaluating these targets for dyslipidemias (Arrowhead, 2021b; Arrowhead, 2021a).

Whether TGs are causal risk factors or simply associative biomarkers remains uncertain not only for ASCVDs but also for other diseases of different organ systems. Understanding the causal effects of TGs across a broader range of human diseases could have significant implications for drug repurposing. TG-lowering agents, such as fibrates (Frick et al., 1987; Ginsberg et al., 2010) and omega-3 fatty acids Bhatt et al., 2019 have already been approved; however, not knowing which diseases are causally affected by TGs precludes their use for indications other than hypertriglyceridemia. Understanding the protective effects of TGs could also have implications for drug safety. With the recent approval of icosapent ethyl (Bhatt et al., 2019; Gaba et al., 2022) and the ongoing development of other TG-lowering agents (Shaik and Rosenson, 2021), such as ANGPTL3 (Graham et al., 2017; Dewey et al., 2017), ANGPTL4, and APOC3 inhibitors (Gaudet et al., 2015), long-term safety becomes a matter of concern. Post-market surveillance data are limited; therefore, identifying diseases with negative causal links to TGs could suggest adverse side effects, whereas protective causal links to TGs could suggest therapeutic avenues and indices informative for drug development. Furthermore, this could inform polypharmacy and drug titration in clinical practice.

Several methodological challenges have prohibited causal conclusions about TGs across human diseases. First, TGs are correlated with established ASCVD risk factors, such as obesity and insulin resistance (Eckel et al., 2005). They also correlate with LDL particles or apolipoprotein B (apoB) concentration (Cromwell et al., 2007) and inversely correlated with high-density lipoprotein cholesterol (HDL-C) (Phillips and Smith, 1991). Conventional observational studies have thus been limited in drawing causal inferences due to potential confounding. Second, available TG-lowering agents have pleiotropic effects on several major lipid fractions, including VLDL-C, LDL-C, HDL-C, and apolipoproteins, including APOC3 (Ginsberg et al., 2010; Keech et al., 2005; Frick et al., 1987). Thus, costly RCTs have had limited power to disentangle the effects of lowering TG specifically (Sarwar et al., 2010; Goldberg et al., 2011; Bhatt et al., 2019). Finally, MR studies have typically focused on individual diseases selected a priori (Davey Smith and Hemani, 2014), narrowing the scope of causal estimates to ASCVDs while overlooking non-ASCVD diseases (Harrison et al., 2018; Smith et al., 2014; Allara et al., 2019).

Phenome-wide MR is a high-throughput extension of MR that estimates the causal effects of an exposure on multiple outcomes simultaneously. As in conventional MR, this method uses genetic variants as instrumental variables (IV) to proxy modifiable exposures (Smith and Ebrahim, 2003), and importantly, it relies on three critical assumptions: (1) The genetic variant is directly associated with the exposure; (2) The genetic variant is unrelated to confounders between the exposure and outcome; and (3) The genetic variant has no effect on the outcome other than through the exposure (Smith and Ebrahim, 2003). A distinction, however, is that phenome-wide MR enables comprehensive scans of the phenotypic spectrum, limiting bias from prior assumptions and facilitating the discovery of unforeseen causal relationships. This has recently become feasible with the maturation of large-scale biobanks providing extensive genetic and phenotypic data, such as the UK Biobank (UKB) (Bycroft et al., 2018) and FinnGen project (FinnGen, 2020).

Here, we use phenome-wide MR to systematically estimate the causal effects of plasma TGs on 2600 disease outcomes in UKB, followed by replication testing in FinnGen. We then apply multiple MR methods for sensitivity analyses and MVMR to control for plasma LDL-C, HDL-C, and ApoB levels.

We performed phenome-wide, two-sample MR to estimate the causal effects of plasma TG levels on a spectrum of human disease traits (n=2600) using a discovery cohort from UKB and a replication cohort from FinnGen. We report seven disease traits reaching Bonferroni-corrected significance in both the discovery and replication analyses, which we categorized as tier 1 results. These traits were predominantly manifestations of ASCVD, such as ischemic heart disease, angina pectoris, and myocardial infarction. Using MVMR, we found that these associations remained even after controlling for LDL-C, HDL-C, and ApoB levels (Figure 4). We also identified three disease traits that are Bonferroni-significant in discovery (p<1.92 × 10^–5) and at least nominally significant in replication (p<0.05), categorized as tier 2 results. Lastly, we identified nine disease traits at least nominally significant in discovery and Bonferroni-significant in replication, categorized as tier 3 results. Several of these non-ASCVD disease traits have never been reported to be causally associated with TGs, potentially introducing new opportunities for drug repurposing and experimental study.

Our results are consistent with prior work suggesting that plasma TG levels are causally associated with ASCVD risk (Sarwar et al., 2010; Castañer et al., 2020; Do et al., 2013; Dewey et al., 2016; Holmes et al., 2015; White et al., 2016; Varbo et al., 2013; Ibi et al., 2021; Rosenson et al., 2021). We do not prove here that circulating TGs per se are directly atherogenic; rather, we show that plasma TG measurement, which comprises multiple classes of triglyceride-rich lipoproteins (TRL) and their remnants, captures a clinically significant mechanism that is causally associated with ASCVD (Rosenson et al., 2021). This interpretation is consistent with an emerging view that apolipoprotein B (ApoB) particle number is a more important determinant of atherogenesis than LDL-C and that TRL particles are as important a risk factor in ASCVD as LDL particles since they each carry a single ApoB molecule (Ference et al., 2019; Marston et al., 2022; Richardson et al., 2020). According to this paradigm, the causal association we observe between plasma TG levels and ASCVD risk may be mediated by the concentration of ApoB particles in TRLs, captured by plasma TG level measurements. We evaluated this possibility by accounting for ApoB levels in a MVMR framework and found that significant causal associations persist between plasma TG levels and all examined ASCVD traits, despite a modest decrease in effect size (Figure 4; Supplementary file 4). These data suggest that ApoB levels may explain at least a portion of the detected associations; however, plasma TG measurement appears to capture additional mechanisms of ASCVD risk involving cholesterol-enriched TRL remnants that remain unclear. Scientific interest in the atherogenic mechanisms of TRLs continues to grow, as recently reviewed elsewhere (Borén et al., 2022; Ginsberg et al., 2021).

Regarding non-ASCVDs, we present suggestive genetic evidence of potentially causal associations between plasma TG levels and uterine leiomyomas (uterine fibroids), diverticular disease of the intestine, paroxysmal tachycardia, hemorrhage from respiratory passages (hemoptysis), and calculus of kidney and ureter (kidney stones). Due to the weaker statistical evidence supporting these associations, special caution is encouraged when interpreting these results to infer causality, and further replication and validation studies are essential for all tier 2 and 3 results. Nevertheless, prior studies have reported correlational associations between many of these diseases and plasma TG levels or risk factors correlated to plasma TGs. For example, studies had documented positive correlations between leiomyoma risk and plasma TG levels (Uimari et al., 2016; Tonoyan et al., 2021; Peshkova et al., 2020). Others had shown diverticular disease risk is positively associated with BMI, body fat percentage, and visceral fat area (Shih et al., 2022; Freckelton et al., 2018; Böhm, 2021). Similarly, kidney stones have been associated with the triglyceride-glucose (TyG) index (Qin et al., 2021), and atrial tachycardias have been associated with VLDL levels in metabolic syndrome patients (Lee et al., 2017; Park and Lee, 2018). Our study is the first to suggest that these associations may be causally related and specific to plasma TG levels, as opposed to confounding risk factors, such as obesity and hormone replacement therapy. However, we note that these associations were not as robust as those in tier 1 associations related to ASCVDs, and we encourage caution in drawing causal conclusions from these estimates of a causal effect. Though, we present the rationale for potentially repurposing TG-lowering agents towards these non-ASCVD indications and for pursuing mechanistic studies interrogating TG biology, RCTs remain the gold standard for assessing causality and remain necessary for assessing clinical potential.

Our results also suggest a novel, negative causal association between plasma TG levels and alcoholic liver disease (ALD), suggesting that excessively reducing plasma TG levels may increase the risk of this disease trait. A mechanistic explanation for this association remains elusive as previous studies on dysregulated lipid metabolism in liver disease have generally focused on non-alcoholic fatty liver disease (NAFLD). However, one animal study suggests that medium-chain TGs may decrease lipid peroxidation and reverse established alcoholic liver injury in rat models of ALD (Nanji et al., 1996). Nevertheless, that elevated TG levels may protect against ALD is surprising and requires external validation. It remains unclear whether this association is only relevant to lifelong, chronic lowering of plasma TG levels rather than transient lowering by drug-based interventions. It is also unclear whether ALD could be prevented by increasing TG levels. This finding suggests the potential intolerability of TG-lowering agents and the importance of maintaining these drugs’ concentrations within therapeutic windows for patient safety; however, we reiterate that this tier 3 association was only nominally significant in discovery, while Bonferroni-significant in replication, and future studies are needed to validate the statistical evidence.

The study has several limitations. First, MR is a powerful but potentially fallible method that relies on several key assumptions, namely that genetic instruments are (i) associated with the exposure (the relevance assumption); (ii) have no common cause with the outcome (the independence assumption); and (iii) have effects on the outcome solely through the exposure (the exclusion restriction assumption) (Hartwig et al., 2016). In MR, (i) is relatively straightforward to test, while (ii) and (iii) are difficult to establish unequivocally. As a prominent example, horizontal or type I pleiotropy has been shown to be common in genetic variation, which can bias MR estimates (Verbanck et al., 2018; Jordan et al., 2019). This occurs when a genetic instrument is associated with multiple traits other than the outcome of interest. To detect and correct for this as best as possible, we used various MR tests as sensitivity analyses that each aims to adjust for or account for the presence of horizontal pleiotropy, including MR-PRESSO, as well as MR-Egger and weighted median methods. There is no universally accepted method that is perfectly robust to horizontal pleiotropy, but we take the best current approach by using multiple methods and examining the consistency of results. A second limitation of the study is that genetic variants confer exposures that are lifelong but small in effect size; thus, MR may over- or underestimate the effect sizes of pharmacological interventions. MR also cannot make comparisons between TG-lowering agents as it evaluates drug targets, not drug subclasses and unique pharmacodynamics (Gill et al., 2019; Sofat et al., 2010). However, the utility of MR in drug target validation is well-established as estimates still indicate the presence and direction of causality (Gill et al., 2021). Third, UKB and FinnGen have innate differences in participant demographics and medical coding systems, due in part to the former being based in the United Kingdom and the latter in Finland. As such, the potential misclassification of participants in the case-control assignment is a liability to this study. We exercised caution in mapping UKB traits to FinnGen traits, but we were unable to reliably map all ‘categorical’ traits from UKB to corresponding traits in FinnGen, testing for replication only 221 of the 598 associations that were nominally significant in the primary analysis. We note however that, despite geographical differences, both datasets largely involve White European participants of older age, with the mean age in UKB and FinnGen being 56.5 and 59.8, respectively. Fourth, discovery and replication analyses were not completely independent, since UKB data were used in both analyses. This could potentially exacerbate demographic and measurement biases inherent to UKB; however, we show that taking a traditional replication approach using GLGC instead of UKB for selecting exposure instruments in replication returns comparable tier 1 results (Supplementary file 5), while losing statistical power to highlight many of the tier 2 and 3 results. Fifth, the GLGC GWAS used to select instruments for plasma TG levels in discovery had accounted for lipid-lowering treatment, while the UKB GWAS used in replication had not. Last, we acknowledge that this study was restricted to populations of European ancestry, limiting the generalizability of our findings. A recent study observed comparable MR estimates for the causal effects of lipid traits on ischemic stroke risk between African and European ancestry individuals (Fatumo et al., 2021), suggesting the potential generalizability of MR results across ancestries in some specific cases. Nevertheless, trans-ancestry MR analyses are warranted to validate our study’s findings in diverse ancestry populations.

In conclusion, this study demonstrates a high-throughput application of two-sample MR to estimate the causal effects of plasma TG levels on phenome-wide disease risk. Future studies may consider the functional and qualitative attributes of TRL subtypes, and metabolomic data partitioning TRLs by size and composition may soon enable this to identify the specific component of a plasma TG measurement that drives disease risk in the detected associations (Holmes et al., 2015). With the proliferation of multi-omic data, this systematic MR approach could be generalized to study the causal effects of serum biomarkers on disease risk, at scale. However, caution is still warranted in inferring causality, as MR depends on specific assumptions and the validity of those assumptions must be carefully assessed. Thus, diverse study designs remain necessary to triangulate evidence on the causal effects of plasma TG levels.

All data generated in this study are included in the manuscript and supplementary tables. All analyses used publicly available data (UKB , FinnGen), including previously published GWAS (GLGC) (Willer et al., 2013). Obtaining access to UKB (Pan-UKB_Team, 2020) and FinnGen (FinnGen, 2020) GWAS summary statistics is detailed here (https://www.finngen.fi/en/access_results) and here (https://pan.ukbb.broadinstitute.org/downloads). Please note the summary statistics for FinnGen and Pan-UKB are made publicly available.

1. 1. Albrink MJ
   2. Man EB

   (1959) Serum triglycerides in coronary artery disease

   A.M.A. Archives of Internal Medicine 103:4–8.

   https://doi.org/10.1001/archinte.1959.00270010010002

   • PubMed
   • Google Scholar
2. 1. Allara E
   2. Morani G
   3. Carter P
   4. Gkatzionis A
   5. Zuber V
   6. Foley CN
   7. Rees JMB
   8. Mason AM
   9. Bell S
   10. Gill D
   11. Lindström S
   12. Butterworth AS
   13. Di Angelantonio E
   14. Peters J
   15. Burgess S
   16. INVENT consortium

   (2019) Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled Mendelian randomization investigation

   Circulation. Genomic and Precision Medicine 12:e002711.

   https://doi.org/10.1161/CIRCGEN.119.002711

   • PubMed
   • Google Scholar
3. Book

   1. Arrowhead

   (2021a)

   Study of ARO-ANG3 in AdultsWith Mixed Dyslipidemia (ARCHES-2)

   U.S.National Library of Medicine.

   • Google Scholar
4. Book

   1. Arrowhead

   (2021b)

   Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)

   U.S. National Library of Medicine.

   • Google Scholar
5. 1. Auton A
   2. Brooks LD
   3. Durbin RM
   4. Garrison EP
   5. Kang HM
   6. Korbel JO
   7. Marchini JL
   8. McCarthy S
   9. McVean GA
   10. Abecasis GR
   11. 1000 Genomes Project Consortium

   (2015) A global reference for human genetic variation

   Nature 526:68–74.

   https://doi.org/10.1038/nature15393

   • PubMed
   • Google Scholar
6. 1. Baigent C
   2. Keech A
   3. Kearney PM
   4. Blackwell L
   5. Buck G
   6. Pollicino C
   7. Kirby A
   8. Sourjina T
   9. Peto R
   10. Collins R
   11. Simes R
   12. Cholesterol Treatment Trialists’ (CTT) Collaborators

   (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

   Lancet 366:1267–1278.

   https://doi.org/10.1016/S0140-6736(05)67394-1

   • PubMed
   • Google Scholar
7. 1. Bhatt DL
   2. Steg PG
   3. Miller M
   4. Brinton EA
   5. Jacobson TA
   6. Ketchum SB
   7. Doyle RT Jr
   8. Juliano RA
   9. Jiao L
   10. Granowitz C
   11. Tardif J-C
   12. Ballantyne CM
   13. REDUCE-IT Investigators

   (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia

   The New England Journal of Medicine 380:11–22.

   https://doi.org/10.1056/NEJMoa1812792

   • PubMed
   • Google Scholar
8. 1. Böhm SK

   (2021) Excessive body weight and diverticular disease

   Visceral Medicine 37:372–382.

   https://doi.org/10.1159/000518674

   • PubMed
   • Google Scholar
9. 1. Borén J
   2. Taskinen MR
   3. Björnson E
   4. Packard CJ

   (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

   Nature Reviews. Cardiology 19:577–592.

   https://doi.org/10.1038/s41569-022-00676-y

   • PubMed
   • Google Scholar
10. 1. Bowden J
    2. Davey Smith G
    3. Burgess S

    (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression

    International Journal of Epidemiology 44:512–525.

    https://doi.org/10.1093/ije/dyv080

    • PubMed
    • Google Scholar
11. 1. Bowden J
    2. Davey Smith G
    3. Haycock PC
    4. Burgess S

    (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator

    Genetic Epidemiology 40:304–314.

    https://doi.org/10.1002/gepi.21965

    • PubMed
    • Google Scholar
12. 1. Burgess S
    2. Butterworth A
    3. Thompson SG

    (2013) Mendelian randomization analysis with multiple genetic variants using summarized data

    Genetic Epidemiology 37:658–665.

    https://doi.org/10.1002/gepi.21758

    • PubMed
    • Google Scholar
13. 1. Burgess S
    2. Davies NM
    3. Thompson SG

    (2016) Bias due to participant overlap in two-sample Mendelian randomization

    Genetic Epidemiology 40:597–608.

    https://doi.org/10.1002/gepi.21998

    • PubMed
    • Google Scholar
14. 1. Burgess S
    2. Davey Smith G
    3. Davies NM
    4. Dudbridge F
    5. Gill D
    6. Glymour MM
    7. Hartwig FP
    8. Holmes MV
    9. Minelli C
    10. Relton CL
    11. Theodoratou E

    (2020) Guidelines for performing mendelian randomization investigations

    Wellcome Open Research 4:186.

    https://doi.org/10.12688/wellcomeopenres.15555.2

    • PubMed
    • Google Scholar
15. 1. Bycroft C
    2. Freeman C
    3. Petkova D
    4. Band G
    5. Elliott LT
    6. Sharp K
    7. Motyer A
    8. Vukcevic D
    9. Delaneau O
    10. O’Connell J
    11. Cortes A
    12. Welsh S
    13. Young A
    14. Effingham M
    15. McVean G
    16. Leslie S
    17. Allen N
    18. Donnelly P
    19. Marchini J

    (2018) The UK Biobank resource with deep phenotyping and genomic data

    Nature 562:203–209.

    https://doi.org/10.1038/s41586-018-0579-z

    • PubMed
    • Google Scholar
16. 1. Castañer O
    2. Pintó X
    3. Subirana I
    4. Amor AJ
    5. Ros E
    6. Hernáez Á
    7. Martínez-González MÁ
    8. Corella D
    9. Salas-Salvadó J
    10. Estruch R
    11. Lapetra J
    12. Gómez-Gracia E
    13. Alonso-Gomez AM
    14. Fiol M
    15. Serra-Majem L
    16. Corbella E
    17. Benaiges D
    18. Sorli JV
    19. Ruiz-Canela M
    20. Babió N
    21. Sierra LT
    22. Ortega E
    23. Fitó M

    (2020) Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease

    Journal of the American College of Cardiology 76:2712–2724.

    https://doi.org/10.1016/j.jacc.2020.10.008

    • PubMed
    • Google Scholar
17. 1. Cromwell WC
    2. Otvos JD
    3. Keyes MJ
    4. Pencina MJ
    5. Sullivan L
    6. Vasan RS
    7. Wilson PWF
    8. D’Agostino RB

    (2007) Ldl particle number and risk of future cardiovascular disease in the Framingham offspring study-implications for LDL management

    Journal of Clinical Lipidology 1:583–592.

    https://doi.org/10.1016/j.jacl.2007.10.001

    • PubMed
    • Google Scholar
18. 1. Crosby J
    2. Peloso GM
    3. Auer PL
    4. Crosslin DR
    5. Stitziel NO
    6. Lange LA
    7. Lu Y
    8. Tang Z
    9. Zhang H
    10. Hindy G
    11. Masca N
    12. Stirrups K
    13. Kanoni S
    14. Do R
    15. Jun G
    16. Hu Y
    17. Kang HM
    18. Xue C
    19. Goel A
    20. Farrall M
    21. Duga S
    22. Merlini PA
    23. Asselta R
    24. Girelli D
    25. Olivieri O
    26. Martinelli N
    27. Yin W
    28. Reilly D
    29. Speliotes E
    30. Fox CS
    31. Hveem K
    32. Holmen OL
    33. Nikpay M
    34. Farlow DN
    35. Assimes TL
    36. Franceschini N
    37. Robinson J
    38. North KE
    39. Martin LW
    40. DePristo M
    41. Gupta N
    42. Escher SA
    43. Jansson J-H
    44. Van Zuydam N
    45. Palmer CNA
    46. Wareham N
    47. Koch W
    48. Meitinger T
    49. Peters A
    50. Lieb W
    51. Erbel R
    52. Konig IR
    53. Kruppa J
    54. Degenhardt F
    55. Gottesman O
    56. Bottinger EP
    57. O’Donnell CJ
    58. Psaty BM
    59. Ballantyne CM
    60. Abecasis G
    61. Ordovas JM
    62. Melander O
    63. Watkins H
    64. Orho-Melander M
    65. Ardissino D
    66. Loos RJF
    67. McPherson R
    68. Willer CJ
    69. Erdmann J
    70. Hall AS
    71. Samani NJ
    72. Deloukas P
    73. Schunkert H
    74. Wilson JG
    75. Kooperberg C
    76. Rich SS
    77. Tracy RP
    78. Lin D-Y
    79. Altshuler D
    80. Gabriel S
    81. Nickerson DA
    82. Jarvik GP
    83. Cupples LA
    84. Reiner AP
    85. Boerwinkle E
    86. Kathiresan S
    87. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute

    (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease

    The New England Journal of Medicine 371:22–31.

    https://doi.org/10.1056/NEJMoa1307095

    • PubMed
    • Google Scholar
19. 1. Davey Smith G
    2. Hemani G

    (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies

    Human Molecular Genetics 23:R89–R98.

    https://doi.org/10.1093/hmg/ddu328

    • PubMed
    • Google Scholar
20. 1. Davies NM
    2. Holmes MV
    3. Davey Smith G

    (2018) Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians

    BMJ 362:k601.

    https://doi.org/10.1136/bmj.k601

    • PubMed
    • Google Scholar
21. 1. Deloukas P
    2. Kanoni S
    3. Willenborg C
    4. Farrall M
    5. Assimes TL
    6. Thompson JR
    7. Ingelsson E
    8. Saleheen D
    9. Erdmann J
    10. Goldstein BA
    11. Stirrups K
    12. König IR
    13. Cazier JB
    14. Johansson A
    15. Hall AS
    16. Lee JY
    17. Willer CJ
    18. Chambers JC
    19. Esko T
    20. Folkersen L
    21. Goel A
    22. Grundberg E
    23. Havulinna AS
    24. Ho WK
    25. Hopewell JC
    26. Eriksson N
    27. Kleber ME
    28. Kristiansson K
    29. Lundmark P
    30. Lyytikäinen LP
    31. Rafelt S
    32. Shungin D
    33. Strawbridge RJ
    34. Thorleifsson G
    35. Tikkanen E
    36. Van Zuydam N
    37. Voight BF
    38. Waite LL
    39. Zhang W
    40. Ziegler A
    41. Absher D
    42. Altshuler D
    43. Balmforth AJ
    44. Barroso I
    45. Braund PS
    46. Burgdorf C
    47. Claudi-Boehm S
    48. Cox D
    49. Dimitriou M
    50. Do R
    51. Doney ASF
    52. El Mokhtari N
    53. Eriksson P
    54. Fischer K
    55. Fontanillas P
    56. Franco-Cereceda A
    57. Gigante B
    58. Groop L
    59. Gustafsson S
    60. Hager J
    61. Hallmans G
    62. Han BG
    63. Hunt SE
    64. Kang HM
    65. Illig T
    66. Kessler T
    67. Knowles JW
    68. Kolovou G
    69. Kuusisto J
    70. Langenberg C
    71. Langford C
    72. Leander K
    73. Lokki ML
    74. Lundmark A
    75. McCarthy MI
    76. Meisinger C
    77. Melander O
    78. Mihailov E
    79. Maouche S
    80. Morris AD
    81. Müller-Nurasyid M
    82. Nikus K
    83. Peden JF
    84. Rayner NW
    85. Rasheed A
    86. Rosinger S
    87. Rubin D
    88. Rumpf MP
    89. Schäfer A
    90. Sivananthan M
    91. Song C
    92. Stewart AFR
    93. Tan ST
    94. Thorgeirsson G
    95. van der Schoot CE
    96. Wagner PJ
    97. Wells GA
    98. Wild PS
    99. Yang TP
    100. Amouyel P
    101. Arveiler D
    102. Basart H
    103. Boehnke M
    104. Boerwinkle E
    105. Brambilla P
    106. Cambien F
    107. Cupples AL
    108. de Faire U
    109. Dehghan A
    110. Diemert P
    111. Epstein SE
    112. Evans A
    113. Ferrario MM
    114. Ferrières J
    115. Gauguier D
    116. Go AS
    117. Goodall AH
    118. Gudnason V
    119. Hazen SL
    120. Holm H
    121. Iribarren C
    122. Jang Y
    123. Kähönen M
    124. Kee F
    125. Kim HS
    126. Klopp N
    127. Koenig W
    128. Kratzer W
    129. Kuulasmaa K
    130. Laakso M
    131. Laaksonen R
    132. Lee JY
    133. Lind L
    134. Ouwehand WH
    135. Parish S
    136. Park JE
    137. Pedersen NL
    138. Peters A
    139. Quertermous T
    140. Rader DJ
    141. Salomaa V
    142. Schadt E
    143. Shah SH
    144. Sinisalo J
    145. Stark K
    146. Stefansson K
    147. Trégouët DA
    148. Virtamo J
    149. Wallentin L
    150. Wareham N
    151. Zimmermann ME
    152. Nieminen MS
    153. Hengstenberg C
    154. Sandhu MS
    155. Pastinen T
    156. Syvänen AC
    157. Hovingh GK
    158. Dedoussis G
    159. Franks PW
    160. Lehtimäki T
    161. Metspalu A
    162. Zalloua PA
    163. Siegbahn A
    164. Schreiber S
    165. Ripatti S
    166. Blankenberg SS
    167. Perola M
    168. Clarke R
    169. Boehm BO
    170. O’Donnell C
    171. Reilly MP
    172. März W
    173. Collins R
    174. Kathiresan S
    175. Hamsten A
    176. Kooner JS
    177. Thorsteinsdottir U
    178. Danesh J
    179. Palmer CNA
    180. Roberts R
    181. Watkins H
    182. Schunkert H
    183. Samani NJ
    184. DIAGRAM Consortium
    185. CARDIOGENICS Consortium
    186. MuTHER Consortium
    187. Wellcome Trust Case Control Consortium
    188. CARDIoGRAMplusC4D Consortium

    (2013) Large-scale association analysis identifies new risk loci for coronary artery disease

    Nature Genetics 45:25–33.

    https://doi.org/10.1038/ng.2480

    • PubMed
    • Google Scholar
22. 1. Dewey FE
    2. Gusarova V
    3. O’Dushlaine C
    4. Gottesman O
    5. Trejos J
    6. Hunt C
    7. Van Hout CV
    8. Habegger L
    9. Buckler D
    10. Lai K-MV
    11. Leader JB
    12. Murray MF
    13. Ritchie MD
    14. Kirchner HL
    15. Ledbetter DH
    16. Penn J
    17. Lopez A
    18. Borecki IB
    19. Overton JD
    20. Reid JG
    21. Carey DJ
    22. Murphy AJ
    23. Yancopoulos GD
    24. Baras A
    25. Gromada J
    26. Shuldiner AR

    (2016) Inactivating variants in ANGPTL4 and risk of coronary artery disease

    The New England Journal of Medicine 374:1123–1133.

    https://doi.org/10.1056/NEJMoa1510926

    • PubMed
    • Google Scholar
23. 1. Dewey FE
    2. Gusarova V
    3. Dunbar RL
    4. O’Dushlaine C
    5. Schurmann C
    6. Gottesman O
    7. McCarthy S
    8. Van Hout CV
    9. Bruse S
    10. Dansky HM
    11. Leader JB
    12. Murray MF
    13. Ritchie MD
    14. Kirchner HL
    15. Habegger L
    16. Lopez A
    17. Penn J
    18. Zhao A
    19. Shao W
    20. Stahl N
    21. Murphy AJ
    22. Hamon S
    23. Bouzelmat A
    24. Zhang R
    25. Shumel B
    26. Pordy R
    27. Gipe D
    28. Herman GA
    29. Sheu WHH
    30. Lee I-T
    31. Liang K-W
    32. Guo X
    33. Rotter JI
    34. Chen Y-DI
    35. Kraus WE
    36. Shah SH
    37. Damrauer S
    38. Small A
    39. Rader DJ
    40. Wulff AB
    41. Nordestgaard BG
    42. Tybjærg-Hansen A
    43. van den Hoek AM
    44. Princen HMG
    45. Ledbetter DH
    46. Carey DJ
    47. Overton JD
    48. Reid JG
    49. Sasiela WJ
    50. Banerjee P
    51. Shuldiner AR
    52. Borecki IB
    53. Teslovich TM
    54. Yancopoulos GD
    55. Mellis SJ
    56. Gromada J
    57. Baras A

    (2017) Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease

    The New England Journal of Medicine 377:211–221.

    https://doi.org/10.1056/NEJMoa1612790

    • PubMed
    • Google Scholar
24. 1. Do R
    2. Willer CJ
    3. Schmidt EM
    4. Sengupta S
    5. Gao C
    6. Peloso GM
    7. Gustafsson S
    8. Kanoni S
    9. Ganna A
    10. Chen J
    11. Buchkovich ML
    12. Mora S
    13. Beckmann JS
    14. Bragg-Gresham JL
    15. Chang H-Y
    16. Demirkan A
    17. Den Hertog HM
    18. Donnelly LA
    19. Ehret GB
    20. Esko T
    21. Feitosa MF
    22. Ferreira T
    23. Fischer K
    24. Fontanillas P
    25. Fraser RM
    26. Freitag DF
    27. Gurdasani D
    28. Heikkilä K
    29. Hyppönen E
    30. Isaacs A
    31. Jackson AU
    32. Johansson A
    33. Johnson T
    34. Kaakinen M
    35. Kettunen J
    36. Kleber ME
    37. Li X
    38. Luan J
    39. Lyytikäinen L-P
    40. Magnusson PKE
    41. Mangino M
    42. Mihailov E
    43. Montasser ME
    44. Müller-Nurasyid M
    45. Nolte IM
    46. O’Connell JR
    47. Palmer CD
    48. Perola M
    49. Petersen A-K
    50. Sanna S
    51. Saxena R
    52. Service SK
    53. Shah S
    54. Shungin D
    55. Sidore C
    56. Song C
    57. Strawbridge RJ
    58. Surakka I
    59. Tanaka T
    60. Teslovich TM
    61. Thorleifsson G
    62. Van den Herik EG
    63. Voight BF
    64. Volcik KA
    65. Waite LL
    66. Wong A
    67. Wu Y
    68. Zhang W
    69. Absher D
    70. Asiki G
    71. Barroso I
    72. Been LF
    73. Bolton JL
    74. Bonnycastle LL
    75. Brambilla P
    76. Burnett MS
    77. Cesana G
    78. Dimitriou M
    79. Doney ASF
    80. Döring A
    81. Elliott P
    82. Epstein SE
    83. Eyjolfsson GI
    84. Gigante B
    85. Goodarzi MO
    86. Grallert H
    87. Gravito ML
    88. Groves CJ
    89. Hallmans G
    90. Hartikainen A-L
    91. Hayward C
    92. Hernandez D
    93. Hicks AA
    94. Holm H
    95. Hung Y-J
    96. Illig T
    97. Jones MR
    98. Kaleebu P
    99. Kastelein JJP
    100. Khaw K-T
    101. Kim E
    102. Klopp N
    103. Komulainen P
    104. Kumari M
    105. Langenberg C
    106. Lehtimäki T
    107. Lin S-Y
    108. Lindström J
    109. Loos RJF
    110. Mach F
    111. McArdle WL
    112. Meisinger C
    113. Mitchell BD
    114. Müller G
    115. Nagaraja R
    116. Narisu N
    117. Nieminen TVM
    118. Nsubuga RN
    119. Olafsson I
    120. Ong KK
    121. Palotie A
    122. Papamarkou T
    123. Pomilla C
    124. Pouta A
    125. Rader DJ
    126. Reilly MP
    127. Ridker PM
    128. Rivadeneira F
    129. Rudan I
    130. Ruokonen A
    131. Samani N
    132. Scharnagl H
    133. Seeley J
    134. Silander K
    135. Stančáková A
    136. Stirrups K
    137. Swift AJ
    138. Tiret L
    139. Uitterlinden AG
    140. van Pelt LJ
    141. Vedantam S
    142. Wainwright N
    143. Wijmenga C
    144. Wild SH
    145. Willemsen G
    146. Wilsgaard T
    147. Wilson JF
    148. Young EH
    149. Zhao JH
    150. Adair LS
    151. Arveiler D
    152. Assimes TL
    153. Bandinelli S
    154. Bennett F
    155. Bochud M
    156. Boehm BO
    157. Boomsma DI
    158. Borecki IB
    159. Bornstein SR
    160. Bovet P
    161. Burnier M
    162. Campbell H
    163. Chakravarti A
    164. Chambers JC
    165. Chen Y-DI
    166. Collins FS
    167. Cooper RS
    168. Danesh J
    169. Dedoussis G
    170. de Faire U
    171. Feranil AB
    172. Ferrières J
    173. Ferrucci L
    174. Freimer NB
    175. Gieger C
    176. Groop LC
    177. Gudnason V
    178. Gyllensten U
    179. Hamsten A
    180. Harris TB
    181. Hingorani A
    182. Hirschhorn JN
    183. Hofman A
    184. Hovingh GK
    185. Hsiung CA
    186. Humphries SE
    187. Hunt SC
    188. Hveem K
    189. Iribarren C
    190. Järvelin M-R
    191. Jula A
    192. Kähönen M
    193. Kaprio J
    194. Kesäniemi A
    195. Kivimaki M
    196. Kooner JS
    197. Koudstaal PJ
    198. Krauss RM
    199. Kuh D
    200. Kuusisto J
    201. Kyvik KO
    202. Laakso M
    203. Lakka TA
    204. Lind L
    205. Lindgren CM
    206. Martin NG
    207. März W
    208. McCarthy MI
    209. McKenzie CA
    210. Meneton P
    211. Metspalu A
    212. Moilanen L
    213. Morris AD
    214. Munroe PB
    215. Njølstad I
    216. Pedersen NL
    217. Power C
    218. Pramstaller PP
    219. Price JF
    220. Psaty BM
    221. Quertermous T
    222. Rauramaa R
    223. Saleheen D
    224. Salomaa V
    225. Sanghera DK
    226. Saramies J
    227. Schwarz PEH
    228. Sheu WH-H
    229. Shuldiner AR
    230. Siegbahn A
    231. Spector TD
    232. Stefansson K
    233. Strachan DP
    234. Tayo BO
    235. Tremoli E
    236. Tuomilehto J
    237. Uusitupa M
    238. van Duijn CM
    239. Vollenweider P
    240. Wallentin L
    241. Wareham NJ
    242. Whitfield JB
    243. Wolffenbuttel BHR
    244. Altshuler D
    245. Ordovas JM
    246. Boerwinkle E
    247. Palmer CNA
    248. Thorsteinsdottir U
    249. Chasman DI
    250. Rotter JI
    251. Franks PW
    252. Ripatti S
    253. Cupples LA
    254. Sandhu MS
    255. Rich SS
    256. Boehnke M
    257. Deloukas P
    258. Mohlke KL
    259. Ingelsson E
    260. Abecasis GR
    261. Daly MJ
    262. Neale BM
    263. Kathiresan S

    (2013) Common variants associated with plasma triglycerides and risk for coronary artery disease

    Nature Genetics 45:1345–1352.

    https://doi.org/10.1038/ng.2795

    • PubMed
    • Google Scholar
25. 1. Doi T
    2. Langsted A
    3. Nordestgaard BG

    (2021) A possible explanation for the contrasting results of REDUCE-IT vs. strength: cohort study mimicking trial designs

    European Heart Journal 42:4807–4817.

    https://doi.org/10.1093/eurheartj/ehab555

    • PubMed
    • Google Scholar
26. 1. Eckel RH
    2. Grundy SM
    3. Zimmet PZ

    (2005) The metabolic syndrome

    Lancet 365:1415–1428.

    https://doi.org/10.1016/S0140-6736(05)66378-7

    • PubMed
    • Google Scholar
27. 1. Fatumo S
    2. Karhunen V
    3. Chikowore T
    4. Sounkou T
    5. Udosen B
    6. Ezenwa C
    7. Nakabuye M
    8. Soremekun O
    9. Daghlas I
    10. Ryan DK
    11. Taylor A
    12. Mason AM
    13. Damrauer SM
    14. Vujkovic M
    15. Keene KL
    16. Fornage M
    17. Järvelin MR
    18. Burgess S
    19. Gill D

    (2021) Metabolic traits and stroke risk in individuals of African ancestry: Mendelian randomization analysis

    Stroke 52:2680–2684.

    https://doi.org/10.1161/STROKEAHA.121.034747

    • PubMed
    • Google Scholar
28. 1. Ference BA
    2. Kastelein JJP
    3. Ray KK
    4. Ginsberg HN
    5. Chapman MJ
    6. Packard CJ
    7. Laufs U
    8. Oliver-Williams C
    9. Wood AM
    10. Butterworth AS
    11. Di Angelantonio E
    12. Danesh J
    13. Nicholls SJ
    14. Bhatt DL
    15. Sabatine MS
    16. Catapano AL

    (2019) Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease

    JAMA 321:364–373.

    https://doi.org/10.1001/jama.2018.20045

    • PubMed
    • Google Scholar
29. Website

    1. FinnGen

    (2020) FinnGen Documentation of R4 Release

    Accessed February 3, 2021.

    https://finngen.gitbook.io/documentation/
30. 1. Freckelton J
    2. Holt D
    3. Borsaru A
    4. Gwini S
    5. Croagh D
    6. Moore G

    (2018) The role of body composition in diverticular disease

    International Journal of Colorectal Disease 33:1299–1302.

    https://doi.org/10.1007/s00384-018-3058-y

    • PubMed
    • Google Scholar
31. 1. Frick MH
    2. Elo O
    3. Haapa K
    4. Heinonen OP
    5. Heinsalmi P
    6. Helo P
    7. Huttunen JK
    8. Kaitaniemi P
    9. Koskinen P
    10. Manninen V
    11. Mäenpää H
    12. Mälkönen M
    13. Mänttäri M
    14. Norola S
    15. Pasternack A
    16. Pikkarainen J
    17. Romo M
    18. Sjöblom T
    19. Nikkilä EA

    (1987) Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia

    New England Journal of Medicine 317:1237–1245.

    https://doi.org/10.1056/NEJM198711123172001

    • Google Scholar
32. 1. Fry A
    2. Littlejohns TJ
    3. Sudlow C
    4. Doherty N
    5. Adamska L
    6. Sprosen T
    7. Collins R
    8. Allen NE

    (2017) Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population

    American Journal of Epidemiology 186:1026–1034.

    https://doi.org/10.1093/aje/kwx246

    • PubMed
    • Google Scholar
33. 1. Gaba P
    2. Bhatt DL
    3. Steg PG
    4. Miller M
    5. Brinton EA
    6. Jacobson TA
    7. Ketchum SB
    8. Juliano RA
    9. Jiao L
    10. Doyle RT Jr
    11. Granowitz C
    12. Tardif J-C
    13. Giugliano RP
    14. Martens FMAC
    15. Gibson CM
    16. Ballantyne CM
    17. REDUCE-IT Investigators

    (2022) Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction

    Journal of the American College of Cardiology 79:1660–1671.

    https://doi.org/10.1016/j.jacc.2022.02.035

    • PubMed
    • Google Scholar
34. 1. Gaudet D
    2. Alexander VJ
    3. Baker BF
    4. Brisson D
    5. Tremblay K
    6. Singleton W
    7. Geary RS
    8. Hughes SG
    9. Viney NJ
    10. Graham MJ
    11. Crooke RM
    12. Witztum JL
    13. Brunzell JD
    14. Kastelein JJP

    (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia

    The New England Journal of Medicine 373:438–447.

    https://doi.org/10.1056/NEJMoa1400283

    • PubMed
    • Google Scholar
35. 1. Gaudet D
    2. Gipe DA
    3. Pordy R
    4. Ahmad Z
    5. Cuchel M
    6. Shah PK
    7. Chyu KY
    8. Sasiela WJ
    9. Chan KC
    10. Brisson D
    11. Khoury E
    12. Banerjee P
    13. Gusarova V
    14. Gromada J
    15. Stahl N
    16. Yancopoulos GD
    17. Hovingh GK

    (2017) Angptl3 inhibition in homozygous familial hypercholesterolemia

    The New England Journal of Medicine 377:296–297.

    https://doi.org/10.1056/NEJMc1705994

    • PubMed
    • Google Scholar
36. 1. Gill D
    2. Georgakis MK
    3. Koskeridis F
    4. Jiang L
    5. Feng Q
    6. Wei WQ
    7. Theodoratou E
    8. Elliott P
    9. Denny JC
    10. Malik R
    11. Evangelou E
    12. Dehghan A
    13. Dichgans M
    14. Tzoulaki I

    (2019) Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects

    Circulation 140:270–279.

    https://doi.org/10.1161/CIRCULATIONAHA.118.038814

    • PubMed
    • Google Scholar
37. 1. Gill D
    2. Georgakis MK
    3. Walker VM
    4. Schmidt AF
    5. Gkatzionis A
    6. Freitag DF
    7. Finan C
    8. Hingorani AD
    9. Howson JMM
    10. Burgess S
    11. Swerdlow DI
    12. Davey Smith G
    13. Holmes MV
    14. Dichgans M
    15. Scott RA
    16. Zheng J
    17. Psaty BM
    18. Davies NM

    (2021) Mendelian randomization for studying the effects of perturbing drug targets

    Wellcome Open Research 6:16.

    https://doi.org/10.12688/wellcomeopenres.16544.2

    • PubMed
    • Google Scholar
38. 1. Ginsberg HN
    2. Elam MB
    3. Lovato LC
    4. Crouse JR
    5. Leiter LA
    6. Linz P
    7. Friedewald WT
    8. Buse JB
    9. Gerstein HC
    10. Probstfield J
    11. Grimm RH
    12. Ismail-Beigi F
    13. Bigger JT
    14. Goff DC
    15. Cushman WC
    16. Simons-Morton DG
    17. Byington RP
    18. ACCORD Study Group

    (2010) Effects of combination lipid therapy in type 2 diabetes mellitus

    The New England Journal of Medicine 362:1563–1574.

    https://doi.org/10.1056/NEJMoa1001282

    • PubMed
    • Google Scholar
39. 1. Ginsberg HN
    2. Packard CJ
    3. Chapman MJ
    4. Borén J
    5. Aguilar-Salinas CA
    6. Averna M
    7. Ference BA
    8. Gaudet D
    9. Hegele RA
    10. Kersten S
    11. Lewis GF
    12. Lichtenstein AH
    13. Moulin P
    14. Nordestgaard BG
    15. Remaley AT
    16. Staels B
    17. Stroes ESG
    18. Taskinen M-R
    19. Tokgözoğlu LS
    20. Tybjaerg-Hansen A
    21. Stock JK
    22. Catapano AL

    (2021) Triglyceride-Rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis Society

    European Heart Journal 42:4791–4806.

    https://doi.org/10.1093/eurheartj/ehab551

    • PubMed
    • Google Scholar
40. 1. Goldberg IJ
    2. Eckel RH
    3. McPherson R

    (2011) Triglycerides and heart disease: still a hypothesis?

    Arteriosclerosis, Thrombosis, and Vascular Biology 31:1716–1725.

    https://doi.org/10.1161/ATVBAHA.111.226100

    • PubMed
    • Google Scholar
41. 1. Göring HH
    2. Terwilliger JD
    3. Blangero J

    (2001) Large upward bias in estimation of locus-specific effects from genomewide scans

    American Journal of Human Genetics 69:1357–1369.

    https://doi.org/10.1086/324471

    • PubMed
    • Google Scholar
42. 1. Graham MJ
    2. Lee RG
    3. Brandt TA
    4. Tai LJ
    5. Fu W
    6. Peralta R
    7. Yu R
    8. Hurh E
    9. Paz E
    10. McEvoy BW
    11. Baker BF
    12. Pham NC
    13. Digenio A
    14. Hughes SG
    15. Geary RS
    16. Witztum JL
    17. Crooke RM
    18. Tsimikas S

    (2017) Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides

    The New England Journal of Medicine 377:222–232.

    https://doi.org/10.1056/NEJMoa1701329

    • PubMed
    • Google Scholar
43. 1. Harrison SC
    2. Holmes MV
    3. Burgess S
    4. Asselbergs FW
    5. Jones GT
    6. Baas AF
    7. van ’t Hof FN
    8. de Bakker PIW
    9. Blankensteijn JD
    10. Powell JT
    11. Saratzis A
    12. de Borst GJ
    13. Swerdlow DI
    14. van der Graaf Y
    15. van Rij AM
    16. Carey DJ
    17. Elmore JR
    18. Tromp G
    19. Kuivaniemi H
    20. Sayers RD
    21. Samani NJ
    22. Bown MJ
    23. Humphries SE

    (2018) Genetic association of lipids and lipid drug targets with abdominal aortic aneurysm: a meta-analysis

    JAMA Cardiology 3:26–33.

    https://doi.org/10.1001/jamacardio.2017.4293

    • PubMed
    • Google Scholar
44. 1. Hartwig FP
    2. Davies NM
    3. Hemani G
    4. Davey Smith G

    (2016) Two-Sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique

    International Journal of Epidemiology 45:1717–1726.

    https://doi.org/10.1093/ije/dyx028

    • PubMed
    • Google Scholar
45. 1. Holmes MV
    2. Asselbergs FW
    3. Palmer TM
    4. Drenos F
    5. Lanktree MB
    6. Nelson CP
    7. Dale CE
    8. Padmanabhan S
    9. Finan C
    10. Swerdlow DI
    11. Tragante V
    12. van Iperen EPA
    13. Sivapalaratnam S
    14. Shah S
    15. Elbers CC
    16. Shah T
    17. Engmann J
    18. Giambartolomei C
    19. White J
    20. Zabaneh D
    21. Sofat R
    22. McLachlan S
    23. UCLEB consortium
    24. Doevendans PA
    25. Balmforth AJ
    26. Hall AS
    27. North KE
    28. Almoguera B
    29. Hoogeveen RC
    30. Cushman M
    31. Fornage M
    32. Patel SR
    33. Redline S
    34. Siscovick DS
    35. Tsai MY
    36. Karczewski KJ
    37. Hofker MH
    38. Verschuren WM
    39. Bots ML
    40. van der Schouw YT
    41. Melander O
    42. Dominiczak AF
    43. Morris R
    44. Ben-Shlomo Y
    45. Price J
    46. Kumari M
    47. Baumert J
    48. Peters A
    49. Thorand B
    50. Koenig W
    51. Gaunt TR
    52. Humphries SE
    53. Clarke R
    54. Watkins H
    55. Farrall M
    56. Wilson JG
    57. Rich SS
    58. de Bakker PIW
    59. Lange LA
    60. Davey Smith G
    61. Reiner AP
    62. Talmud PJ
    63. Kivimäki M
    64. Lawlor DA
    65. Dudbridge F
    66. Samani NJ
    67. Keating BJ
    68. Hingorani AD
    69. Casas JP

    (2015) Mendelian randomization of blood lipids for coronary heart disease

    European Heart Journal 36:539–550.

    https://doi.org/10.1093/eurheartj/eht571

    • PubMed
    • Google Scholar
46. 1. Ibi D
    2. Blauw LL
    3. Noordam R
    4. Dollé MET
    5. Jukema JW
    6. Rosendaal FR
    7. Christodoulides C
    8. Neville MJ
    9. Koivula R
    10. Rensen PCN
    11. Karpe F
    12. van Dijk KW

    (2021) Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles are associated with an additively improved lipoprotein profile

    Atherosclerosis 328:144–152.

    https://doi.org/10.1016/j.atherosclerosis.2021.04.015

    • PubMed
    • Google Scholar
47. 1. Jordan DM
    2. Verbanck M
    3. Do R

    (2019) HOPS: a quantitative score reveals pervasive horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of human traits and diseases

    Genome Biology 20:222.

    https://doi.org/10.1186/s13059-019-1844-7

    • PubMed
    • Google Scholar
48. 1. Keech A
    2. Simes RJ
    3. Barter P
    4. Best J
    5. Scott R
    6. Taskinen MR
    7. Forder P
    8. Pillai A
    9. Davis T
    10. Glasziou P
    11. Drury P
    12. Kesäniemi YA
    13. Sullivan D
    14. Hunt D
    15. Colman P
    16. d’Emden M
    17. Whiting M
    18. Ehnholm C
    19. Laakso M
    20. FIELD study investigators

    (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the field study): randomised controlled trial

    Lancet 366:1849–1861.

    https://doi.org/10.1016/S0140-6736(05)67667-2

    • PubMed
    • Google Scholar
49. 1. Kurki MI
    2. Karjalainen J
    3. Palta P
    4. Sipilä TP
    5. Kristiansson K
    6. Donner K
    7. Reeve MP
    8. Laivuori H
    9. Aavikko M
    10. Kaunisto MA
    11. Loukola A
    12. Lahtela E
    13. Mattsson H
    14. Laiho P
    15. Della Briotta Parolo P
    16. Lehisto A
    17. Kanai M
    18. Mars N
    19. Rämö J
    20. Kiiskinen T
    21. Heyne HO
    22. Veerapen K
    23. Rüeger S
    24. Lemmelä S
    25. Zhou W
    26. Ruotsalainen S
    27. Pärn K
    28. Hiekkalinna T
    29. Koskelainen S
    30. Paajanen T
    31. Llorens V
    32. Gracia-Tabuenca J
    33. Siirtola H
    34. Reis K
    35. Elnahas AG
    36. Aalto-Setälä K
    37. Alasoo K
    38. Arvas M
    39. Auro K
    40. Biswas S
    41. Bizaki-Vallaskangas A
    42. Carpen O
    43. Chen CY
    44. Dada OA
    45. Ding Z
    46. Ehm MG
    47. Eklund K
    48. Färkkilä M
    49. Finucane H
    50. Ganna A
    51. Ghazal A
    52. Graham RR
    53. Green E
    54. Hakanen A
    55. Hautalahti M
    56. Hedman Å
    57. Hiltunen M
    58. Hinttala R
    59. Hovatta I
    60. Hu X
    61. Huertas-Vazquez A
    62. Huilaja L
    63. Hunkapiller J
    64. Jacob H
    65. Jensen JN
    66. Joensuu H
    67. John S
    68. Julkunen V
    69. Jung M
    70. Junttila J
    71. Kaarniranta K
    72. Kähönen M
    73. Kajanne RM
    74. Kallio L
    75. Kälviäinen R
    76. Kaprio J
    77. Kerimov N
    78. Kettunen J
    79. Kilpeläinen E
    80. Kilpi T
    81. Klinger K
    82. Kosma VM
    83. Kuopio T
    84. Kurra V
    85. Laisk T
    86. Laukkanen J
    87. Lawless N
    88. Liu A
    89. Longerich S
    90. Mägi R
    91. Mäkelä J
    92. Mäkitie A
    93. Malarstig A
    94. Mannermaa A
    95. Maranville J
    96. Matakidou A
    97. Meretoja T
    98. Mozaffari SV
    99. Niemi MEK
    100. Niemi M
    101. Niiranen T
    102. O’Donnell CJ
    103. Obeidat M
    104. Okafo G
    105. Ollila HM
    106. Palomäki A
    107. Palotie T
    108. Partanen J
    109. Paul DS
    110. Pelkonen M
    111. Pendergrass RK
    112. Petrovski S
    113. Pitkäranta A
    114. Platt A
    115. Pulford D
    116. Punkka E
    117. Pussinen P
    118. Raghavan N
    119. Rahimov F
    120. Rajpal D
    121. Renaud NA
    122. Riley-Gillis B
    123. Rodosthenous R
    124. Saarentaus E
    125. Salminen A
    126. Salminen E
    127. Salomaa V
    128. Schleutker J
    129. Serpi R
    130. Shen H
    131. Siegel R
    132. Silander K
    133. Siltanen S
    134. Soini S
    135. Soininen H
    136. Sul JH
    137. Tachmazidou I
    138. Tasanen K
    139. Tienari P
    140. Toppila-Salmi S
    141. Tukiainen T
    142. Tuomi T
    143. Turunen JA
    144. Ulirsch JC
    145. Vaura F
    146. Virolainen P
    147. Waring J
    148. Waterworth D
    149. Yang R
    150. Nelis M
    151. Reigo A
    152. Metspalu A
    153. Milani L
    154. Esko T
    155. Fox C
    156. Havulinna AS
    157. Perola M
    158. Ripatti S
    159. Jalanko A
    160. Laitinen T
    161. Mäkelä T
    162. Plenge R
    163. McCarthy M
    164. Runz H
    165. Daly MJ
    166. Palotie A

    (2022) FinnGen: unique genetic insights from combining isolated population and national health register data

    Genetic and Genomic Medicine 1:22271360.

    https://doi.org/10.1101/2022.03.03.22271360

    • Google Scholar
50. 1. Lee HC
    2. Chen CC
    3. Tsai WC
    4. Lin HT
    5. Shiao YL
    6. Sheu SH
    7. Wu BN
    8. Chen CH
    9. Lai WT

    (2017) Very-low-density lipoprotein of metabolic syndrome modulates gap junctions and slows cardiac conduction

    Scientific Reports 7:12050.

    https://doi.org/10.1038/s41598-017-11416-5

    • PubMed
    • Google Scholar
51. 1. Marston NA
    2. Giugliano RP
    3. Melloni GEM
    4. Park JG
    5. Morrill V
    6. Blazing MA
    7. Ference B
    8. Stein E
    9. Stroes ES
    10. Braunwald E
    11. Ellinor PT
    12. Lubitz SA
    13. Ruff CT
    14. Sabatine MS

    (2022) Association of apolipoprotein B–containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis

    JAMA Cardiology 7:250.

    https://doi.org/10.1001/jamacardio.2021.5083

    • Google Scholar
52. 1. Miller M
    2. Stone NJ
    3. Ballantyne C
    4. Bittner V
    5. Criqui MH
    6. Ginsberg HN
    7. Goldberg AC
    8. Howard WJ
    9. Jacobson MS
    10. Kris-Etherton PM
    11. Lennie TA
    12. Levi M
    13. Mazzone T
    14. Pennathur S

    (2011) Triglycerides and cardiovascular disease

    Circulation 123:2292–2333.

    https://doi.org/10.1161/CIR.0b013e3182160726

    • PubMed
    • Google Scholar
53. 1. Musunuru K
    2. Pirruccello JP
    3. Do R
    4. Peloso GM
    5. Guiducci C
    6. Sougnez C
    7. Garimella KV
    8. Fisher S
    9. Abreu J
    10. Barry AJ
    11. Fennell T
    12. Banks E
    13. Ambrogio L
    14. Cibulskis K
    15. Kernytsky A
    16. Gonzalez E
    17. Rudzicz N
    18. Engert JC
    19. DePristo MA
    20. Daly MJ
    21. Cohen JC
    22. Hobbs HH
    23. Altshuler D
    24. Schonfeld G
    25. Gabriel SB
    26. Yue P
    27. Kathiresan S

    (2010) Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia

    The New England Journal of Medicine 363:2220–2227.

    https://doi.org/10.1056/NEJMoa1002926

    • PubMed
    • Google Scholar
54. 1. Nanji AA
    2. Yang EK
    3. Fogt F
    4. Sadrzadeh SM
    5. Dannenberg AJ

    (1996)

    Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease

    The Journal of Pharmacology and Experimental Therapeutics 277:1694–1700.

    • PubMed
    • Google Scholar
55. 1. Nicholls SJ
    2. Lincoff AM
    3. Garcia M
    4. Bash D
    5. Ballantyne CM
    6. Barter PJ
    7. Davidson MH
    8. Kastelein JJP
    9. Koenig W
    10. McGuire DK
    11. Mozaffarian D
    12. Ridker PM
    13. Ray KK
    14. Katona BG
    15. Himmelmann A
    16. Loss LE
    17. Rensfeldt M
    18. Lundström T
    19. Agrawal R
    20. Menon V
    21. Wolski K
    22. Nissen SE

    (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the strength randomized clinical trial

    JAMA 324:2268–2280.

    https://doi.org/10.1001/jama.2020.22258

    • PubMed
    • Google Scholar
56. 1. Norata GD
    2. Grigore L
    3. Raselli S
    4. Redaelli L
    5. Hamsten A
    6. Maggi F
    7. Eriksson P
    8. Catapano AL

    (2007) Post-Prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies

    Atherosclerosis 193:321–327.

    https://doi.org/10.1016/j.atherosclerosis.2006.09.015

    • PubMed
    • Google Scholar
57. Website

    1. PanUKBTeam

    (2020) Pan-UK Biobank

    Accessed February 1, 2021.

    https://pan.ukbb.broadinstitute.org
58. 1. Park B
    2. Lee YJ

    (2018) Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women

    Journal of Clinical Lipidology 12:1298–1304.

    https://doi.org/10.1016/j.jacl.2018.07.004

    • PubMed
    • Google Scholar
59. 1. Peshkova T
    2. Nakashidze I
    3. Petrovic N
    4. Beridze S
    5. Kedelidze N
    6. Artmeladze M
    7. Kamashidze K

    (2020) 73 Study of lipid profile and thyroid hormones in patients with uterine fibroids

    International Journal of Gynecologic Cancer 30:A41.

    https://doi.org/10.1136/ijgc-2020-IGCS.69

    • Google Scholar
60. 1. Phillips AN
    2. Smith GD

    (1991) How independent are “independent” effects? relative risk estimation when correlated exposures are measured imprecisely

    Journal of Clinical Epidemiology 44:1223–1231.

    https://doi.org/10.1016/0895-4356(91)90155-3

    • PubMed
    • Google Scholar
61. 1. Purcell S
    2. Neale B
    3. Todd-Brown K
    4. Thomas L
    5. Ferreira MAR
    6. Bender D
    7. Maller J
    8. Sklar P
    9. de Bakker PIW
    10. Daly MJ
    11. Sham PC

    (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses

    American Journal of Human Genetics 81:559–575.

    https://doi.org/10.1086/519795

    • PubMed
    • Google Scholar
62. 1. Qin Z
    2. Zhao J
    3. Geng J
    4. Chang K
    5. Liao R
    6. Su B

    (2021) Higher triglyceride-glucose index is associated with increased likelihood of kidney stones

    Frontiers in Endocrinology 12:774567.

    https://doi.org/10.3389/fendo.2021.774567

    • PubMed
    • Google Scholar
63. Software

    1. R Development Core Team

    (2021) R: A language and environment for statistical computing

    R Foundation for Statistical Computing, Vienna, Austria.

    https://www.r-project.org/
64. 1. Richardson TG
    2. Sanderson E
    3. Palmer TM
    4. Ala-Korpela M
    5. Ference BA
    6. Davey Smith G
    7. Holmes MV

    (2020) Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis

    PLOS Medicine 17:e1003062.

    https://doi.org/10.1371/journal.pmed.1003062

    • PubMed
    • Google Scholar
65. 1. Rosenson RS
    2. Goonewardena SN

    (2021) The residual risk odyssey: from LDL to Lp (a)

    Journal of the American College of Cardiology 78:434–436.

    https://doi.org/10.1016/j.jacc.2021.04.103

    • PubMed
    • Google Scholar
66. 1. Rosenson RS
    2. Shaik A
    3. Song W

    (2021) New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3/4

    Journal of the American College of Cardiology 78:1817–1830.

    https://doi.org/10.1016/j.jacc.2021.08.051

    • PubMed
    • Google Scholar
67. 1. Roth GA
    2. Mensah GA
    3. Johnson CO
    4. Addolorato G
    5. Ammirati E
    6. Baddour LM
    7. Barengo NC
    8. Beaton AZ
    9. Benjamin EJ
    10. Benziger CP
    11. Bonny A
    12. Brauer M
    13. Brodmann M
    14. Cahill TJ
    15. Carapetis J
    16. Catapano AL
    17. Chugh SS
    18. Cooper LT
    19. Coresh J
    20. Criqui M
    21. DeCleene N
    22. Eagle KA
    23. Emmons-Bell S
    24. Feigin VL
    25. Fernández-Solà J
    26. Fowkes G
    27. Gakidou E
    28. Grundy SM
    29. He FJ
    30. Howard G
    31. Hu F
    32. Inker L
    33. Karthikeyan G
    34. Kassebaum N
    35. Koroshetz W
    36. Lavie C
    37. Lloyd-Jones D
    38. Lu HS
    39. Mirijello A
    40. Temesgen AM
    41. Mokdad A
    42. Moran AE
    43. Muntner P
    44. Narula J
    45. Neal B
    46. Ntsekhe M
    47. Moraes de Oliveira G
    48. Otto C
    49. Owolabi M
    50. Pratt M
    51. Rajagopalan S
    52. Reitsma M
    53. Ribeiro ALP
    54. Rigotti N
    55. Rodgers A
    56. Sable C
    57. Shakil S
    58. Sliwa-Hahnle K
    59. Stark B
    60. Sundström J
    61. Timpel P
    62. Tleyjeh IM
    63. Valgimigli M
    64. Vos T
    65. Whelton PK
    66. Yacoub M
    67. Zuhlke L
    68. Murray C
    69. Fuster V
    70. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group

    (2020) Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study

    Journal of the American College of Cardiology 76:2982–3021.

    https://doi.org/10.1016/j.jacc.2020.11.010

    • PubMed
    • Google Scholar
68. 1. Sanderson E

    (2021) Multivariable Mendelian randomization and mediation

    Cold Spring Harbor Perspectives in Medicine 11:a038984.

    https://doi.org/10.1101/cshperspect.a038984

    • PubMed
    • Google Scholar
69. 1. Sarwar N
    2. Sandhu MS
    3. Ricketts SL
    4. Butterworth AS
    5. Di Angelantonio E
    6. Boekholdt SM
    7. Ouwehand W
    8. Watkins H
    9. Samani NJ
    10. Saleheen D
    11. Lawlor D
    12. Reilly MP
    13. Hingorani AD
    14. Talmud PJ
    15. Danesh J
    16. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration

    (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

    Lancet 375:1634–1639.

    https://doi.org/10.1016/S0140-6736(10)60545-4

    • PubMed
    • Google Scholar
70. 1. Shaik A
    2. Rosenson RS

    (2021) Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction

    Cardiovascular Drugs and Therapy 35:677–690.

    https://doi.org/10.1007/s10557-021-07168-0

    • PubMed
    • Google Scholar
71. 1. Shih CW
    2. Chen YH
    3. Chen WL

    (2022) Percentage of body fat is associated with increased risk of diverticulosis: a cross sectional study

    PLOS ONE 17:e0264746.

    https://doi.org/10.1371/journal.pone.0264746

    • PubMed
    • Google Scholar
72. 1. Skrivankova VW
    2. Richmond RC
    3. Woolf BAR
    4. Yarmolinsky J
    5. Davies NM
    6. Swanson SA
    7. VanderWeele TJ
    8. Higgins JPT
    9. Timpson NJ
    10. Dimou N
    11. Langenberg C
    12. Golub RM
    13. Loder EW
    14. Gallo V
    15. Tybjaerg-Hansen A
    16. Davey Smith G
    17. Egger M
    18. Richards JB

    (2021) Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement

    JAMA 326:1614–1621.

    https://doi.org/10.1001/jama.2021.18236

    • PubMed
    • Google Scholar
73. 1. Smith GD
    2. Ebrahim S

    (2003) “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease?

    International Journal of Epidemiology 32:1–22.

    https://doi.org/10.1093/ije/dyg070

    • PubMed
    • Google Scholar
74. 1. Smith JG
    2. Luk K
    3. Schulz C-A
    4. Engert JC
    5. Do R
    6. Hindy G
    7. Rukh G
    8. Dufresne L
    9. Almgren P
    10. Owens DS
    11. Harris TB
    12. Peloso GM
    13. Kerr KF
    14. Wong Q
    15. Smith AV
    16. Budoff MJ
    17. Rotter JI
    18. Cupples LA
    19. Rich S
    20. Kathiresan S
    21. Orho-Melander M
    22. Gudnason V
    23. O’Donnell CJ
    24. Post WS
    25. Thanassoulis G
    26. Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Extracoronary Calcium Working Group

    (2014) Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis

    JAMA 312:1764–1771.

    https://doi.org/10.1001/jama.2014.13959

    • PubMed
    • Google Scholar
75. 1. Sofat R
    2. Hingorani AD
    3. Smeeth L
    4. Humphries SE
    5. Talmud PJ
    6. Cooper J
    7. Shah T
    8. Sandhu MS
    9. Ricketts SL
    10. Boekholdt SM
    11. Wareham N
    12. Khaw KT
    13. Kumari M
    14. Kivimaki M
    15. Marmot M
    16. Asselbergs FW
    17. van der Harst P
    18. Dullaart RPF
    19. Navis G
    20. van Veldhuisen DJ
    21. Van Gilst WH
    22. Thompson JF
    23. McCaskie P
    24. Palmer LJ
    25. Arca M
    26. Quagliarini F
    27. Gaudio C
    28. Cambien F
    29. Nicaud V
    30. Poirer O
    31. Gudnason V
    32. Isaacs A
    33. Witteman JCM
    34. van Duijn CM
    35. Pencina M
    36. Vasan RS
    37. D’Agostino RB Sr
    38. Ordovas J
    39. Li TY
    40. Kakko S
    41. Kauma H
    42. Savolainen MJ
    43. Kesäniemi YA
    44. Sandhofer A
    45. Paulweber B
    46. Sorli JV
    47. Goto A
    48. Yokoyama S
    49. Okumura K
    50. Horne BD
    51. Packard C
    52. Freeman D
    53. Ford I
    54. Sattar N
    55. McCormack V
    56. Lawlor DA
    57. Ebrahim S
    58. Smith GD
    59. Kastelein JJP
    60. Deanfield J
    61. Casas JP

    (2010) Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms

    Circulation 121:52–62.

    https://doi.org/10.1161/CIRCULATIONAHA.109.865444

    • PubMed
    • Google Scholar
76. 1. Sudlow C
    2. Gallacher J
    3. Allen N
    4. Beral V
    5. Burton P
    6. Danesh J
    7. Downey P
    8. Elliott P
    9. Green J
    10. Landray M
    11. Liu B
    12. Matthews P
    13. Ong G
    14. Pell J
    15. Silman A
    16. Young A
    17. Sprosen T
    18. Peakman T
    19. Collins R

    (2015) Uk Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age

    PLOS Medicine 12:e1001779.

    https://doi.org/10.1371/journal.pmed.1001779

    • PubMed
    • Google Scholar
77. 1. Tonoyan NM
    2. Chagovets VV
    3. Starodubtseva NL
    4. Tokareva AO
    5. Chingin K
    6. Kozachenko IF
    7. Adamyan LV
    8. Frankevich VE

    (2021) Alterations in lipid profile upon uterine fibroids and its recurrence

    Scientific Reports 11:11447.

    https://doi.org/10.1038/s41598-021-89859-0

    • PubMed
    • Google Scholar
78. 1. Uimari O
    2. Auvinen J
    3. Jokelainen J
    4. Puukka K
    5. Ruokonen A
    6. Järvelin MR
    7. Piltonen T
    8. Keinänen-Kiukaanniemi S
    9. Zondervan K
    10. Järvelä I
    11. Ryynänen M
    12. Martikainen H

    (2016) Uterine fibroids and cardiovascular risk

    Human Reproduction 31:2689–2703.

    https://doi.org/10.1093/humrep/dew249

    • PubMed
    • Google Scholar
79. 1. Varbo A
    2. Benn M
    3. Tybjærg-Hansen A
    4. Jørgensen AB
    5. Frikke-Schmidt R
    6. Nordestgaard BG

    (2013) Remnant cholesterol as a causal risk factor for ischemic heart disease

    Journal of the American College of Cardiology 61:427–436.

    https://doi.org/10.1016/j.jacc.2012.08.1026

    • PubMed
    • Google Scholar
80. 1. Verbanck M
    2. Chen CY
    3. Neale B
    4. Do R

    (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases

    Nature Genetics 50:693–698.

    https://doi.org/10.1038/s41588-018-0099-7

    • PubMed
    • Google Scholar
81. 1. White J
    2. Swerdlow DI
    3. Preiss D
    4. Fairhurst-Hunter Z
    5. Keating BJ
    6. Asselbergs FW
    7. Sattar N
    8. Humphries SE
    9. Hingorani AD
    10. Holmes MV

    (2016) Association of lipid fractions with risks for coronary artery disease and diabetes

    JAMA Cardiology 1:692–699.

    https://doi.org/10.1001/jamacardio.2016.1884

    • PubMed
    • Google Scholar
82. 1. Willer CJ
    2. Schmidt EM
    3. Sengupta S
    4. Peloso GM
    5. Gustafsson S
    6. Kanoni S
    7. Ganna A
    8. Chen J
    9. Buchkovich ML
    10. Mora S
    11. Beckmann JS
    12. Bragg-Gresham JL
    13. Chang H-Y
    14. Demirkan A
    15. Den Hertog HM
    16. Do R
    17. Donnelly LA
    18. Ehret GB
    19. Esko T
    20. Feitosa MF
    21. Ferreira T
    22. Fischer K
    23. Fontanillas P
    24. Fraser RM
    25. Freitag DF
    26. Gurdasani D
    27. Heikkilä K
    28. Hyppönen E
    29. Isaacs A
    30. Jackson AU
    31. Johansson Å
    32. Johnson T
    33. Kaakinen M
    34. Kettunen J
    35. Kleber ME
    36. Li X
    37. Luan J
    38. Lyytikäinen L-P
    39. Magnusson PKE
    40. Mangino M
    41. Mihailov E
    42. Montasser ME
    43. Müller-Nurasyid M
    44. Nolte IM
    45. O’Connell JR
    46. Palmer CD
    47. Perola M
    48. Petersen A-K
    49. Sanna S
    50. Saxena R
    51. Service SK
    52. Shah S
    53. Shungin D
    54. Sidore C
    55. Song C
    56. Strawbridge RJ
    57. Surakka I
    58. Tanaka T
    59. Teslovich TM
    60. Thorleifsson G
    61. Van den Herik EG
    62. Voight BF
    63. Volcik KA
    64. Waite LL
    65. Wong A
    66. Wu Y
    67. Zhang W
    68. Absher D
    69. Asiki G
    70. Barroso I
    71. Been LF
    72. Bolton JL
    73. Bonnycastle LL
    74. Brambilla P
    75. Burnett MS
    76. Cesana G
    77. Dimitriou M
    78. Doney ASF
    79. Döring A
    80. Elliott P
    81. Epstein SE
    82. Ingi Eyjolfsson G
    83. Gigante B
    84. Goodarzi MO
    85. Grallert H
    86. Gravito ML
    87. Groves CJ
    88. Hallmans G
    89. Hartikainen A-L
    90. Hayward C
    91. Hernandez D
    92. Hicks AA
    93. Holm H
    94. Hung Y-J
    95. Illig T
    96. Jones MR
    97. Kaleebu P
    98. Kastelein JJP
    99. Khaw K-T
    100. Kim E
    101. Klopp N
    102. Komulainen P
    103. Kumari M
    104. Langenberg C
    105. Lehtimäki T
    106. Lin S-Y
    107. Lindström J
    108. Loos RJF
    109. Mach F
    110. McArdle WL
    111. Meisinger C
    112. Mitchell BD
    113. Müller G
    114. Nagaraja R
    115. Narisu N
    116. Nieminen TVM
    117. Nsubuga RN
    118. Olafsson I
    119. Ong KK
    120. Palotie A
    121. Papamarkou T
    122. Pomilla C
    123. Pouta A
    124. Rader DJ
    125. Reilly MP
    126. Ridker PM
    127. Rivadeneira F
    128. Rudan I
    129. Ruokonen A
    130. Samani N
    131. Scharnagl H
    132. Seeley J
    133. Silander K
    134. Stančáková A
    135. Stirrups K
    136. Swift AJ
    137. Tiret L
    138. Uitterlinden AG
    139. van Pelt LJ
    140. Vedantam S
    141. Wainwright N
    142. Wijmenga C
    143. Wild SH
    144. Willemsen G
    145. Wilsgaard T
    146. Wilson JF
    147. Young EH
    148. Zhao JH
    149. Adair LS
    150. Arveiler D
    151. Assimes TL
    152. Bandinelli S
    153. Bennett F
    154. Bochud M
    155. Boehm BO
    156. Boomsma DI
    157. Borecki IB
    158. Bornstein SR
    159. Bovet P
    160. Burnier M
    161. Campbell H
    162. Chakravarti A
    163. Chambers JC
    164. Chen Y-DI
    165. Collins FS
    166. Cooper RS
    167. Danesh J
    168. Dedoussis G
    169. de Faire U
    170. Feranil AB
    171. Ferrières J
    172. Ferrucci L
    173. Freimer NB
    174. Gieger C
    175. Groop LC
    176. Gudnason V
    177. Gyllensten U
    178. Hamsten A
    179. Harris TB
    180. Hingorani A
    181. Hirschhorn JN
    182. Hofman A
    183. Hovingh GK
    184. Hsiung CA
    185. Humphries SE
    186. Hunt SC
    187. Hveem K
    188. Iribarren C
    189. Järvelin M-R
    190. Jula A
    191. Kähönen M
    192. Kaprio J
    193. Kesäniemi A
    194. Kivimaki M
    195. Kooner JS
    196. Koudstaal PJ
    197. Krauss RM
    198. Kuh D
    199. Kuusisto J
    200. Kyvik KO
    201. Laakso M
    202. Lakka TA
    203. Lind L
    204. Lindgren CM
    205. Martin NG
    206. März W
    207. McCarthy MI
    208. McKenzie CA
    209. Meneton P
    210. Metspalu A
    211. Moilanen L
    212. Morris AD
    213. Munroe PB
    214. Njølstad I
    215. Pedersen NL
    216. Power C
    217. Pramstaller PP
    218. Price JF
    219. Psaty BM
    220. Quertermous T
    221. Rauramaa R
    222. Saleheen D
    223. Salomaa V
    224. Sanghera DK
    225. Saramies J
    226. Schwarz PEH
    227. Sheu WH-H
    228. Shuldiner AR
    229. Siegbahn A
    230. Spector TD
    231. Stefansson K
    232. Strachan DP
    233. Tayo BO
    234. Tremoli E
    235. Tuomilehto J
    236. Uusitupa M
    237. van Duijn CM
    238. Vollenweider P
    239. Wallentin L
    240. Wareham NJ
    241. Whitfield JB
    242. Wolffenbuttel BHR
    243. Ordovas JM
    244. Boerwinkle E
    245. Palmer CNA
    246. Thorsteinsdottir U
    247. Chasman DI
    248. Rotter JI
    249. Franks PW
    250. Ripatti S
    251. Cupples LA
    252. Sandhu MS
    253. Rich SS
    254. Boehnke M
    255. Deloukas P
    256. Kathiresan S
    257. Mohlke KL
    258. Ingelsson E
    259. Abecasis GR
    260. Global Lipids Genetics Consortium

    (2013) Discovery and refinement of loci associated with lipid levels

    Nature Genetics 45:1274–1283.

    https://doi.org/10.1038/ng.2797

    • PubMed
    • Google Scholar
83. 1. Yu X
    2. Wang T
    3. Huang S
    4. Zeng P

    (2021) Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis

    Journal of Human Genetics 66:465–473.

    https://doi.org/10.1038/s10038-020-00863-0

    • PubMed
    • Google Scholar
84. 1. Zewinger S
    2. Reiser J
    3. Jankowski V
    4. Alansary D
    5. Hahm E
    6. Triem S
    7. Klug M
    8. Schunk SJ
    9. Schmit D
    10. Kramann R
    11. Körbel C
    12. Ampofo E
    13. Laschke MW
    14. Selejan S-R
    15. Paschen A
    16. Herter T
    17. Schuster S
    18. Silbernagel G
    19. Sester M
    20. Sester U
    21. Aßmann G
    22. Bals R
    23. Kostner G
    24. Jahnen-Dechent W
    25. Menger MD
    26. Rohrer L
    27. März W
    28. Böhm M
    29. Jankowski J
    30. Kopf M
    31. Latz E
    32. Niemeyer BA
    33. Fliser D
    34. Laufs U
    35. Speer T

    (2020) Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation

    Nature Immunology 21:30–41.

    https://doi.org/10.1038/s41590-019-0548-1

    • PubMed
    • Google Scholar

Author details

1. Joshua K Park

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
   3. Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Data curation, Formal analysis, Investigation, Writing - original draft, Writing – review and editing

   Contributed equally with

   Shantanu Bafna

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-1719-3537

2. Shantanu Bafna

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Data curation, Formal analysis, Investigation, Writing - original draft, Writing – review and editing

   Contributed equally with

   Joshua K Park

   Competing interests

   No competing interests declared

3. Iain S Forrest

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
   3. Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Formal analysis, Validation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

4. Áine Duffy

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Resources, Validation, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

5. Carla Marquez-Luna

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Supervision, Validation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

6. Ben O Petrazzini

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Resources, Supervision, Investigation, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

7. Ha My Vy

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Resources, Data curation, Supervision, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

8. Daniel M Jordan

   1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
   2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Supervision, Investigation, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

9. Marie Verbanck

   Université Paris Cité, Paris, France

   Contribution

   Investigation, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

10. Jagat Narula

    1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Cardiovascular Imaging Program, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, United States

    Contribution

    Resources, Data curation, Supervision, Writing – review and editing

    Competing interests

    No competing interests declared

11. Robert S Rosenson

    1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Metabolism and Lipids Unit, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, United States

    Contribution

    Supervision, Validation, Methodology, Writing – review and editing

    Competing interests

    reports receiving grants from Amgen, Arrowhead, Lilly, Novartis and Regeneron; consulting fees from Amgen, Arrowhead, Lilly, Novartis and Regeneron; honoraria for non-promotional lectures from Amgen, Kowa and Regeneron, royalties from Wolters Kluwer (UpToDate); and stock holdings in MediMergent, LLC

12. Ghislain Rocheleau

    1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

    Contribution

    Resources, Data curation, Supervision, Investigation, Methodology, Writing – review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-9989-7553

13. Ron Do

    1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, United States
    2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

    Contribution

    Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing – review and editing

    For correspondence

    ron.do@mssm.edu

    Competing interests

    reports receiving grants from AstraZeneca; grants and non-financial support from Goldfinch Bio; being a scientific co-founder, consultant, and equity holder (pending) for Pensieve Health; and a consultant for Variant Bio, all unrelated to this work

    "This ORCID iD identifies the author of this article:" 0000-0002-3144-3627

• 1,302

  views

• 160

  downloads

• 2

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.